Chief Scientific Officer
A German national of Indian origin with over 20 years of experience as a scientific innovator working in Academia and Pharmaceutical industry. His career started as Alexander von Humboldt (AvH) fellow at Karlsruhe Institute of Technology (KIT), Germany after completing PhD in Organic Chemistry from North Eastern Hill University (NEHU) Shillong, India in 1994. Since then he has held various senior positions in academia & pharmaceutical industry in Germany and India and worked on several drug discovery projects including integrated with various large-/mid-sized pharma’s along with small biotech and virtual companies and has taken compounds from target to clinic and delivered several optimized leads across diverse therapeutic areas viz., Oncology, Pain & CNS, MD and Antibacterial. Co-inventor of two clinical candidate ASN-001 (NCT02349139) & ASN-007 (NCT 03415126) into first in human clinical Phase I&II trials (NCT02349139) for the treatment of metastatic castration-resistant prostate cancer and metastatic KRAS, NRAS & HRAS mutated solid tumors, respectively. Further two projects are currently at the PCC nomination IND enabling studies.
Published over 50 research publications, patents, invited review articles, perspectives and book chapters. He is a member of several active chemical societies and reviewer of peer reviewed journals and committees.
Dr. Raghava joins LLS from Jubilant Biosys., Bangalore, where he served as Director & Head of Medicinal Chemistry, responsible for all the department scientific and operation functions.